© 2020 MJH Life Sciences and Cancer Network. All rights reserved.
Author | Susan London
Articles
Novel chemoRT regimen ups survival in pancreatic ca
September 29, 2009
In patients with resected pancreatic cancer, adjuvant cisplatin, 5-FU, and interferon chemoradiation produces a median survival of 27 months, according to initial results of the ACOSOG Z05031 trial. However, nearly all patients experience grade 3 or 4 toxicities.
A call for judicious use of diagnostic breast MRI
September 21, 2009
Current evidence does not support the routine use of breast MRI in women with newly diagnosed breast cancer, according to Monica Morrow, MD, chief of the breast service, department of surgery, at Memorial Sloan-Kettering Cancer Center.
Trial links gene to recurrence risk in triple-negative breast cancer
December 15, 2008
Patients with operable triple-negative breast cancer are at increased risk for recurrence if their tumor has higher levels of a protein-encoding gene implicated in migration, proliferation, and other cellular processes, reported Joseph A. Sparano, MD, from the Eastern Cooperative Oncology Group.
Trial establishes neoadjuvant trastuzumab as standard for locally advanced disease
December 15, 2008
Neoadjuvant therapy that includes trastuzumab (Herceptin) prolongs event-free survival and has an acceptable safety profile in women with HER2-positive locally advanced breast cancer, based on results from the largest trial testing such therapy in this setting.